# US 2025/0205193 A1 · Therapeutic compound and salts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205193 A1
- Document ID: US20250205193A1
- Status: Published application
- Kind: A1
- Application number: 18/846,873
- Filed: 2023-03-22
- Published: 2025-06-26
- Earliest claimed: 2022-03-22
- Assignees: Regents of the University of Minnesota
- Applicants: Regents of the University of Minnesota
- Inventors: Venkatram Reddy Mereddy; Zachary Scott Gardner; Tanner James Schumacher
- Web page: https://patentgrep.com/patent/US20250205193A1

## CPC

- A61K 31/37: Coumarins, e.g. psoralen
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 35/00: Antineoplastic agents
- C07C 215/10: with one amino group and at least two hydroxy groups bound to the carbon skeleton
- C07D 311/16: substituted in position 7
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention provides a compound of formula (I) or a salt thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and methods of inhibiting an MPC and treating an MPC related disease or condition.

## Claims

### Claim 1

A compound of formula (I):
or a salt thereof.

### Claim 2 (depends on 1)

The salt of claim 1, which is a pharmaceutically acceptable salt.

### Claim 3 (depends on 1)

The salt of claim 1, which is

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) as described in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 5 (depends on 1, 2, 3)

A method for inhibiting an MPC (in vivo or in vitro), comprising contacting the MPC with a compound of formula (I) or a salt as described in any one of claims 1-3.

### Claim 6 (depends on 1)

A method for treating an MPC related disease or condition (e.g., cancer, non-alcoholic steatohepatitis, diabetes, obesity, or chronic graft versus host disease) in an animal (e.g., a mammal such as a human) comprising administering a compound of formula (I) as described in claim 1 or a pharmaceutically acceptable salt thereof to the animal.

### Claim 7 (depends on 1)

A compound of formula (I) as described in claim 1 or a pharmaceutically acceptable salt thereof for use in medical therapy.

### Claim 8 (depends on 1)

A compound of formula (I) as described in claim 1 or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of an MPC related disease or condition (e.g., cancer, non-alcoholic steatohepatitis, diabetes, obesity, or chronic graft versus host disease).

### Claim 9 (depends on 1)

The use of a compound of formula (I) as described in claim 1 or a pharmaceutically acceptable salt thereof to prepare a medicament for treating an MPC related disease or condition (e.g., cancer, non-alcoholic steatohepatitis, diabetes, obesity, or chronic graft versus host disease) in an animal (e.g. a mammal such as a human).